Raras
Buscar doenças, sintomas, genes...
Narcolepsia tipo 1
ORPHA:2073CID-10 · G47.4CID-11 · 7A20.0DOENÇA RARA

Um tipo de narcolepsia caracterizado por sonolência excessiva durante o dia, acompanhada por uma vontade incontrolável de dormir e cataplexia (que é uma perda repentina de força nos músculos, muitas vezes causada por emoções agradáveis).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um tipo de narcolepsia caracterizado por sonolência excessiva durante o dia, acompanhada por uma vontade incontrolável de dormir e cataplexia (que é uma perda repentina de força nos músculos, muitas vezes causada por emoções agradáveis).

Pesquisas ativas
18 ensaios
43 total registrados no ClinicalTrials.gov
Publicações científicas
663 artigos
Último publicado: 2026 Jan-Dec

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
30.0
Europe
Início
Adolescent
+ adult, childhood
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G47.4
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
4 sintomas
📏
Crescimento
3 sintomas
🧠
Neurológico
3 sintomas
🫁
Pulmão
2 sintomas
🫃
Digestivo
1 sintomas

+ 22 sintomas em outras categorias

Características mais comuns

90%prev.
Amnésia global transitória
Muito frequente (99-80%)
90%prev.
Anormalidade do sono
Muito frequente (99-80%)
90%prev.
Alucinações
Muito frequente (99-80%)
90%prev.
Cataplexia
Muito frequente (99-80%)
90%prev.
Sonolência diurna excessiva
Muito frequente (99-80%)
55%prev.
Nictúria
Frequente (79-30%)
35sintomas
Muito frequente (5)
Frequente (15)
Ocasional (9)
Muito raro (1)
Sem dados (5)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 35 características clínicas mais associadas, ordenadas por frequência.

Amnésia global transitóriaTransient global amnesia
Muito frequente (99-80%)90%
Anormalidade do sonoSleep abnormality
Muito frequente (99-80%)90%
AlucinaçõesHallucinations
Muito frequente (99-80%)90%
CataplexiaCataplexy
Muito frequente (99-80%)90%
Sonolência diurna excessivaExcessive daytime somnolence
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico663PubMed
Últimos 10 anos200publicações
Pico202591 papers
Linha do tempo
2026Hoje · 2026🧪 2010Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

8 genes identificados com associação a esta condição. Padrão de herança: Unknown.

HLA-DRB1HLA class II histocompatibility antigen, DRB1 beta chainMajor susceptibility factor inRestrito
FUNÇÃO

A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneLysosome membraneLate endosome membraneAutolysosome membrane

VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1832.6 TPM
Pulmão
1234.8 TPM
Baço
990.6 TPM
Intestino delgado
607.2 TPM
Nervo tibial
598.3 TPM
OUTRAS DOENÇAS (16)
narcolepsy-cataplexy syndromefollicular lymphomaVogt-Koyanagi-Harada diseasepediatric multiple sclerosis
HGNC:4948UniProt:P01911
P2RY11P2Y purinoceptor 11Major susceptibility factor inTolerante
FUNÇÃO

Receptor for ATP and ADP coupled to G-proteins that activate both phosphatidylinositol-calcium and adenylyl cyclase second messenger systems. Not activated by UTP or UDP

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
G alpha (q) signalling eventsG alpha (s) signalling eventsP2Y receptors
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
42.5 TPM
Skin Sun Exposed Lower leg
26.4 TPM
Skin Not Sun Exposed Suprapubic
24.9 TPM
Testículo
24.1 TPM
Tireoide
23.9 TPM
OUTRAS DOENÇAS (1)
narcolepsy-cataplexy syndrome
HGNC:8540UniProt:Q96G91
HCRTHypocretin neuropeptide precursorMajor susceptibility factor inTolerante
FUNÇÃO

Neuropeptides that play a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested Binds to orexin receptors HCRTR1/OX1R and HCRTR2/OX2R with a high affinity (By similarity). Stimulates food intake (By simil

LOCALIZAÇÃO

Rough endoplasmic reticulumCytoplasmic vesicleSynapse

VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsOrexin and neuropeptides FF and QRFP bind to their respective receptors
MECANISMO DE DOENÇA

Narcolepsy 1

Neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement (REM) sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis. Cataplexy is a sudden loss of muscle tone triggered by emotions, which is the most valuable clinical feature used to diagnose narcolepsy. Human narcolepsy is primarily a sporadically occurring disorder but familial clustering has been observed.

EXPRESSÃO TECIDUAL(Tecido-específico)
Hipotálamo
38.4 TPM
Brain Nucleus accumbens basal ganglia
0.5 TPM
Cérebro - Hemisfério cerebelar
0.4 TPM
Brain Caudate basal ganglia
0.4 TPM
Cerebelo
0.4 TPM
OUTRAS DOENÇAS (3)
narcolepsy 1narcolepsy-cataplexy syndromenarcolepsy without cataplexy
HGNC:4847UniProt:O43612
CTSHPro-cathepsin HMajor susceptibility factor inTolerante
FUNÇÃO

Important for the overall degradation of proteins in lysosomes

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Surfactant metabolism
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
251.6 TPM
Pulmão
169.3 TPM
Rim - Medula
128.9 TPM
Rim - Córtex
112.1 TPM
Cervix Endocervix
102.7 TPM
OUTRAS DOENÇAS (1)
narcolepsy-cataplexy syndrome
HGNC:2535UniProt:P09668
MOGMyelin-oligodendrocyte glycoproteinMajor susceptibility factor inTolerante
FUNÇÃO

Mediates homophilic cell-cell adhesion (By similarity). Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell-cell communication (Microbial infection) Acts as a receptor for rubella virus

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (4)
Maturation of spike proteinMaturation of spike proteinRegulation of CDH1 posttranslational processing and trafficking to plasma membraneN-glycan trimming in the ER and Calnexin/Calreticulin cycle
MECANISMO DE DOENÇA

Narcolepsy 7

Neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement (REM) sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis. Cataplexy is a sudden loss of muscle tone triggered by emotions, which is the most valuable clinical feature used to diagnose narcolepsy. Human narcolepsy is primarily a sporadically occurring disorder but familial clustering has been observed.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Spinal cord cervical c-1
663.1 TPM
Substância negra
183.1 TPM
Hipocampo
148.4 TPM
Brain Putamen basal ganglia
104.8 TPM
Cérebro - Amígdala
81.5 TPM
OUTRAS DOENÇAS (2)
narcolepsy 7narcolepsy-cataplexy syndrome
HGNC:7197UniProt:Q16653
ZNF365TalaninMajor susceptibility factor inTolerante
FUNÇÃO

May play a role in uric acid excretion

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Uric acid nephrolithiasis

A form of nephrolithiasis, a common multifactorial disease characterized by stones formation in the kidney and urinary tract. Nephrolithiasis is due to supersaturation of the urine by stone-forming constituents, including calcium, oxalate and uric acid. Crystals or foreign bodies can act as nidi, upon which ions from the supersaturated urine form microscopic crystalline structures. Uric acid nephrolithiasis occurs when the urine becomes overly concentrated with uric acid and accounts for 20% of all stones.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
36.5 TPM
Córtex cerebral
18.6 TPM
Brain Anterior cingulate cortex BA24
13.3 TPM
Cérebro - Hemisfério cerebelar
11.6 TPM
Brain Spinal cord cervical c-1
11.5 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (3)
narcolepsy-cataplexy syndromenarcolepsy without cataplexynephrolithiasis, uric acid, susceptibility to
HGNC:18194UniProt:Q70YC4
HLA-DQB1HLA class II histocompatibility antigen, DQ beta 1 chainMajor susceptibility factor inTolerante
FUNÇÃO

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membraneGolgi apparatus, trans-Golgi network membraneEndosome membraneLysosome membrane

VIAS BIOLÓGICAS (1)
MHC class II antigen presentation
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
556.8 TPM
Pulmão
197.8 TPM
Baço
189.1 TPM
Tecido adiposo
82.7 TPM
Intestino delgado
75.3 TPM
OUTRAS DOENÇAS (8)
bullous pemphigoidpediatric multiple sclerosisidiopathic achalasianarcolepsy-cataplexy syndrome
HGNC:4944UniProt:P01920
TNFSF4Tumor necrosis factor ligand superfamily member 4Major susceptibility factor inModerado
FUNÇÃO

Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
TNFs bind their physiological receptors
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
9.8 TPM
Fibroblastos
6.5 TPM
Testículo
5.3 TPM
Esôfago - Junção
4.2 TPM
Cérebro - Hemisfério cerebelar
3.7 TPM
OUTRAS DOENÇAS (3)
narcolepsy-cataplexy syndromesystemic lupus erythematosusmyocardial infarction, susceptibility to
HGNC:11934UniProt:P23510

Medicamentos aprovados (FDA)

3 medicamentos encontrados nos registros da FDA americana.

💊 Amphetamine Sulfate (AMPHETAMINE SULFATE)
💊 DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE)
💊 Modafinil (MODAFINIL)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

66 variantes patogênicas registradas no ClinVar.

🧬 TNFSF4: GRCh37/hg19 1q21.1-44(chr1:143932350-249224684)x3 ()
🧬 TNFSF4: GRCh37/hg19 1q24.2-31.1(chr1:167994071-187711459)x1 ()
🧬 TNFSF4: GRCh37/hg19 1q25.1-25.3(chr1:173162501-182702252)x3 ()
🧬 TNFSF4: GRCh37/hg19 1q23.3-25.1(chr1:164571371-175708060)x1 ()
🧬 TNFSF4: GRCh37/hg19 1q24.3-31.3(chr1:171990029-195086758) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 61 variantes classificadas pelo ClinVar.

12
40
9
Patogênica (19.7%)
VUS (65.6%)
Benigna (14.8%)
VARIANTES MAIS SIGNIFICATIVAS
DNMT1: NM_001130823.3(DNMT1):c.4641G>T (p.Glu1547Asp) [Likely pathogenic]
DNMT1: NM_001130823.3(DNMT1):c.3311C>T (p.Ala1104Val) [Conflicting classifications of pathogenicity]
DNMT1: NM_001130823.3(DNMT1):c.1823T>G (p.Leu608Arg) [Likely pathogenic]
DNMT1: NM_001130823.3(DNMT1):c.1678C>T (p.Arg560Cys) [Conflicting classifications of pathogenicity]
DNMT1: NM_001130823.3(DNMT1):c.1756A>G (p.Ser586Gly) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 36
2Fase 24
1Fase 12
·Pré-clínico8
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Narcolepsia tipo 1

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

14 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

43 ensaios clínicos encontrados, 18 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
660 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 660

#1

Patient-reported experiences of cognitive difficulties and their impact on daily life in narcolepsy type 1.

Frontiers in neurology2026

The cognitive difficulties experienced by individuals with narcolepsy type 1 (NT1), a rare and chronic neurological disorder, are understudied, with limited knowledge of their consequences in daily life. Here, we investigated the nature of cognitive difficulties and their consequences for daily life from the perspective of adults with NT1. In-depth, qualitative interviews were conducted with adults diagnosed with NT1 residing in the United States. Participants were recruited through (1) a patient advocacy organization (via social media and website); (2) a professional market research firm; and (3) participant referrals. Individual interviews were conducted by telephone, following a semi-structured guide, and lasted approximately 90 min. Qualitative analysis used an adapted grounded theory approach to identify key conceptual themes related to cognitive difficulties and their impacts on daily life. Of 46 participants, most reported experiencing some cognitive difficulties, with the most common being trouble remembering and difficulty with focus or sustained attention. Most participants characterized their difficulties with cognition as moderate or severe and reported these occurring daily. The qualitative findings informed the development of a conceptual model depicting cognitive difficulties and their broad impact on functioning and well-being in adults with NT1. Cognitive difficulties in adults with NT1 are frequent, severe, and described as interfering with daily life activities and well-being. These data highlight a clear need to assess cognitive function in people with NT1 and identify treatments that address NT1-associated cognitive symptoms.

#2

Increased Numbers of CD4+ T-Cells in the Hypocretin/Orexin Region of Narcolepsy Type 1.

Annals of neurology2026 Mar 14

Narcolepsy type 1 (NT1) is presumed to be an autoimmune disorder caused by hypothalamic loss of hypocretin (Hcrt; orexin). In postmortem NT1 brains, we observed an 11-fold increase of CD4+ T-cells in the Hcrt region compared with control hypothalami, without a corresponding rise in CD8+ T-cells. CD4+ and CD8+ T-cell numbers were unchanged in other hypothalamic regions, including the paraventricular nucleus and median eminence, and in extra-hypothalamic areas such as the substantia nigra and locus coeruleus. Hcrt-region CD4+ T-cells expressed the tissue-resident memory markers CD49a and CXCR6. These findings support the autoimmune hypothesis of NT1. ANN NEUROL 2026.

#3

Bioinformatics identification and experimental validation of hub genes associated with narcolepsy type 1.

Journal of clinical and translational science2026

Narcolepsy type 1 (NT1) is a chronic neurological disorder with a genetic predisposition, yet its precise molecular pathogenesis remains unclear. Despite increasing recognition of its clinical and genetic basis, the precise molecular mechanisms remain unclear. This study aimed to identify NT1-associated hub genes and investigate their biological functions and interactions through comprehensive bioinformatics analysis, followed by experimental validation. NT1-related microarray data (GSE21592) were retrieved from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using integrated analysis with R software and the GEO2R platform. Functional enrichment analyses for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were conducted using Database for Annotation, Visualization, and Integrated Discovery online tool. Protein-protein interaction (PPI) networks were constructed using STRING database and visualized with Cytoscape. Quantitative real-time PCR (qRT-PCR) was used to experimentally validate the expression of identified hub genes in NT1 patients. A total of 148 DEGs were identified. GO analysis revealed involvement primarily in biosynthesis, humoral immune response, viral gene expression, oxidoreductase activity, cytoplasmic translation, etc. KEGG analysis showed enrichment in oxidative phosphorylation, ribosomal pathways, thermogenesis, and glutathione metabolism pathways. Five hub genes - CREB1, PIK3R1, MED1, GATA3, and KDM5A - were identified from the PPI network. qRT-PCR validation confirmed significantly reduced expression of these genes in NT1 patients compared to healthy controls. Our study identified and experimentally validated five critical hub genes associated with NT1, providing new insights into its molecular mechanisms and highlighting potential therapeutic targets for future research and clinical intervention strategies.

#4

Unravelling Narcolepsy: A Series of Complex Pediatric Cases.

Neurology. Clinical practice2026 Apr

Narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) are rare, chronic neurologic disorders of hypersomnolence. Narcolepsy type 1 results from the selective loss of orexin-producing neurons, leading to markedly reduced levels of orexin neuropeptides in the brain and CSF. NT2 shares some symptoms with the former but has no orexin deficiency. Both disorders manifest as a spectrum of debilitating symptoms, including excessive daytime sleepiness (EDS), cataplexy (NT1 only), fragmented nocturnal sleep, sleep paralysis, and hallucinations. Diagnosis is particularly challenging, especially in pediatric patients. We describe 7 pediatric patients presenting with complex narcolepsy phenotype of EDS or cataplexy with a diverse array of comorbid genetic, neurologic, and neuropsychiatric conditions. These cases illustrate the diagnostic challenges in differentiating "primary narcolepsy" from "narcolepsy because of a medical disorder" (e.g., Prader-Willi Syndrome) or "narcolepsy associated with autism spectrum disorder or very early-onset schizophrenia." The patients underwent a comprehensive diagnostic workup, including polysomnography, multiple sleep latency testing (performed after wash-out of concomitant medications), brain magnetic resonance imaging, CSF hypocretin-1 assay, and, in case of consistent clues, autoimmune, and genetic testing. Ensuring accurate and prompt narcolepsy diagnosis allows effective and patient-centered management.

#5

Glymphatic dysfunction and its association with clinical symptom severity in narcolepsy type 1: a case-control DTI-ALPS study.

BMC neurology2026 Jan 28

Narcolepsy type 1 (NT1) is characterized by excessive daytime sleepiness and cataplexy, primarily caused by hypothalamic orexin deficiency. Beyond neurotransmitter dysregulation, recent evidence suggests that impaired metabolic waste clearance may contribute to its pathophysiology. This study aimed to assess glymphatic function in NT1 using diffusion tensor image analysis along the perivascular space (DTI-ALPS) and to explore its relationship with clinical and polysomnographic features. A total of 92 NT1 patients and 45 age- and sex-matched healthy controls underwent 3.0 T DTI and overnight polysomnography. The ALPS index was calculated to quantify glymphatic efficiency. Correlation and regression analyses examined associations between ALPS values and Epworth Sleepiness Scale (ESS), Multiple Sleep Latency Test (MSLT), and other clinical parameters. Receiver operating characteristic (ROC) analysis evaluated the predictive performance of ALPS for NT1 diagnosis. The ALPS index was significantly lower in NT1 patients than in controls (1.24 ± 0.07 vs. 1.33 ± 0.06, P < 0.001), indicating impaired glymphatic function. Reduced ALPS values correlated with higher ESS scores (r = − 0.39, P < 0.001), shorter MSLT latency (r = 0.36, P = 0.002), and greater cataplexy severity. Each 0.1-unit decrease in ALPS increased the odds of NT1 by 2.8-fold (adjusted OR = 2.78, 95% CI 1.43–5.41, P = 0.003). The ALPS index showed good diagnostic accuracy (AUC = 0.81), which improved when combined with MSLT (AUC = 0.87, P = 0.018). NT1 is associated with significant glymphatic dysfunction, and the degree of impairment correlates with symptom severity. The DTI-ALPS index provides a quantitative and noninvasive biomarker that may aid in disease evaluation and individualized management of narcolepsy. The online version contains supplementary material available at 10.1186/s12883-026-04669-z.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC285 artigos no totalmostrando 199

2026

Patient-reported experiences of cognitive difficulties and their impact on daily life in narcolepsy type 1.

Frontiers in neurology
2026

Effects of an orexin receptor 2-selective agonist on salivary secretion in rats.

Scientific reports
2026

Increased Numbers of CD4+ T-Cells in the Hypocretin/Orexin Region of Narcolepsy Type 1.

Annals of neurology
2026

Narcolepsy type 1: an autoimmune disease.

Trends in molecular medicine
2026

Patient-reported outcome measures in central disorders of hypersomnolence: consensus of a sleep consortium/RARE-X expert working group.

Sleep advances : a journal of the Sleep Research Society
2026

Mapping nocturnal arousal across sleep and pain disorders.

Scientific reports
2026

Test-retest repeatability of the multiple sleep latency test in non-cataleptic hypersomnolence disorders.

Sleep medicine
2026

Initial validation of a pediatric cataplexy survey for children and adolescents with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2026

Bioinformatics identification and experimental validation of hub genes associated with narcolepsy type 1.

Journal of clinical and translational science
2026

Clinical significance of ADHD traits in central disorders of hypersomnolence.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2026

Unravelling Narcolepsy: A Series of Complex Pediatric Cases.

Neurology. Clinical practice
2026

iSPHYNCS: Unsupervised Clustering in Questionnaires and Metadata Reveals Distinct Subtypes in the Narcolepsy Borderland.

Journal of sleep research
2025

Differential motor signatures in isolated and narcolepsy-related REM sleep behaviour disorder: a preliminary study.

Frontiers in neurology
2026

High-resolution sleep fragmentation assessment in narcolepsy type 1 and their non-narcoleptic siblings: a 5-second mini-epoch study.

Sleep
2026

Glymphatic dysfunction and its association with clinical symptom severity in narcolepsy type 1: a case-control DTI-ALPS study.

BMC neurology
2026

Disorder-specific alterations of transient oscillatory dynamics during sleep across cortical and subcortical networks.

Scientific reports
2026

Intelligence quotient in adults with idiopathic hypersomnia and narcolepsy type 1.

Sleep medicine
2025

Research Progress in the Roles of Influenza A H1N1 Virus and Its Vaccine in the Pathogenesis of Narcolepsy Type 1.

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2026

Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1.

Annals of medicine and surgery (2012)
2026

Clinical and instrumental comparison between insufficient sleep syndrome and narcolepsy type 1.

Sleep medicine
2025

Mass Spectrometry-Based Quantification of Orexin Species in Human Cerebrospinal Fluid Reveals Differential Dynamics Associated with Sleep.

medRxiv : the preprint server for health sciences
2025

Serum Metabolomic Signatures of Dyslipidemia in Narcolepsy Type 1: A Multi-Center Cross-Sectional Study.

Nature and science of sleep
2025

Causality of blood metabolites and narcolepsy type 1: A Mendelian randomization study.

Medicine
2025

A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1.

Journal of clinical medicine
2025

The Risks of Injury and Accident in Patients With Central Hypersomnia: A Cohort Study in Taiwan.

Journal of sleep research
2026

Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.

JAMA neurology
2025

Clinical pearls for the treatment of narcolepsy.

The mental health clinician
2025

'It's hard to feel this way every single day': patients' perspectives on the emotional burden of narcolepsy.

Frontiers in psychology
2025

Animal Models of Narcolepsy: From Orexin Deficiency to Immune Mechanisms and Regenerative Therapies.

Current issues in molecular biology
2025

Very late-onset narcolepsy type 1: diagnosis in the ninth decade.

BMJ case reports
2025

Hypothalamic functional connectivity, depressive symptoms, and post-treatment SOREMPs in narcolepsy type 1: links to sleep latency and mediation mechanisms.

Translational psychiatry
2026

Association between lipopolysaccharide-binding protein levels and disease severity in pediatric narcolepsy: A cross-sectional study.

Sleep medicine
2025

Circadian Modulation of Sleep-Wake Behavior in Patients with Narcolepsy Type 1 and Idiopathic Hypersomnia.

Nature and science of sleep
2025

Attention and inhibition deficits in narcolepsy type 1: behavioral and electrophysiological markers.

Translational psychiatry
2025

Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers.

Brain and behavior
2025

Underestimation of nocturnal sleep duration in central disorders of hypersomnolence: an underrecognized feature?

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2026

Dynamic Functional Network Connectivity Patterns Distinguish Neurobiological Substrates of Narcolepsy Type 1 and Idiopathic Hypersomnia: Potential Biomarkers From Resting-State fMRI.

Journal of sleep research
2025

DNA methylation and multi-omics profiling of T cells uncovers chemotactic pathways and proliferation-linked hypomethylation in narcolepsy type 1.

Sleep
2026

Feasibility and efficacy of exercise training on sleep symptoms and comorbidities in narcolepsy type 1: a prospective interventional study.

Sleep
2025

Hypocretin: a promising target for the regulation of homeostasis.

Frontiers in neuroscience
2025

Prevalence and Factors Associated with Rapid Eye Movement-Related Obstructive Sleep Apnea in Patients with Narcolepsy.

Nature and science of sleep
2025

Quantification of electromyographic activity during REM sleep in Chinese narcolepsy patients and healthy controls: a comparative study.

Sleep &amp; breathing = Schlaf &amp; Atmung
2025

Narcolepsy 2025 (with an Australasian perspective).

Internal medicine journal
2026

Facial Emotion Recognition in Children With Narcolepsy Type 1.

Journal of sleep research
2025

Beyond neuronal loss: epigenetic signatures bridging immune activation and sleep dysfunction in narcolepsy type 1.

Sleep
2025

Initial experience and establishment of a hypersomnia board: A multidisciplinary approach to complex hypersomnia cases.

Sleep medicine
2026

Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years.

Journal of sleep research
2026

Narcolepsy type 2 is an unstable diagnosis and idiopathic hypersomnia has the potential for remission-long-term and cross-sectional observations from the Bern Sleep-Wake Registry.

Sleep
2025

16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy.

Sleep
2025

Orexin effect on physiological pulsations of the human brain.

Proceedings of the National Academy of Sciences of the United States of America
2026

Corticotropin-Releasing Hormone (CRH) in Murine Narcolepsy: What Do Genetic and Immune Models Tell Us?

Journal of sleep research
2025

The inter-night variability of REM sleep without atonia in adult patients with central disorders of hypersomnolence.

Sleep medicine
2025

Abnormal brain functional network dynamics in narcolepsy type 1 patients.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2025

Alteration of Metabolic Profile in Patients with Narcolepsy Type 1.

Metabolites
2026

Characteristics of maintenance of wakefulness test in drug-naïve patients with narcolepsy type 1 and type 2, and relationship with other measures of sleepiness.

Sleep
2025

Efficacy and safety of pitolisant in children above 6 years with narcolepsy.

Expert opinion on pharmacotherapy
2025

Narcolepsy and psychiatric comorbidity: a review of the literature.

International journal of clinical and health psychology : IJCHP
2025

Narcolepsy and cardiovascular health: A big picture perspective.

Sleep medicine
2025

The Role of Actigraphy in the Assessment of Central Disorders of Hypersomnolence: A Systematic Review and Meta-Analysis.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

Present and Future of Central Disorders of Hypersomnolence.

Journal of sleep research
2025

Probability estimation of narcolepsy type 1 in DTA mice using unlabeled EEG and EMG data.

Sleep advances : a journal of the Sleep Research Society
2025

Benefits of oveporexton in narcolepsy type 1.

Nature reviews. Neurology
2025

Physical performance, health-related quality of life and sleepiness severity of an adult outpatient population with narcolepsy: A cross-sectional analysis.

International journal of clinical and health psychology : IJCHP
2025

Symptoms of central disorders of hypersomnolence during phases of female hormonal transitions: an explorative self-report study.

Sleep medicine
2025

The prevalence, incidence, and impact of narcolepsy and idiopathic hypersomnia in Taiwan: comparison between the National Health Insurance Research Claims Database and a hospital cohort database.

Sleep
2025

Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches.

Seminars in immunology
2025

Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.

The New England journal of medicine
2025

Gender disparities in cognitive impairment across neurological autoimmune disorders: a systematic review.

Frontiers in neurology
2025

Transcutaneous auricular vagus nerve stimulation to treat narcolepsy type 1 (TARGET-NT1): A two-arm, randomised, sham-controlled trial.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2025

Discovery of a New Class of Orexin 2 Receptor Agonists as a Potential Treatment for Narcolepsy.

Journal of medicinal chemistry
2025

Post-vaccination hypersomnia - occurrence of idiopathic hypersomnia and narcolepsy type 2 after Pandemrix vaccination in a case- series from Sweden and Finland.

Journal of the neurological sciences
2025

Case Report: Narcolepsy patients masked behind obstructive sleep apnea syndrome (OSAS): report of 2 cases and literature review.

Frontiers in neuroscience
2025

Narcolepsy Beyond Medication: A Scoping Review of Psychological and Behavioral Interventions for Patients with Narcolepsy.

Journal of clinical medicine
2025

Elevated circulating cell-free mitochondrial DNA level in cerebrospinal fluid of narcolepsy type 1.

Brain communications
2025

Sex effect on disease characteristics in patients with narcolepsy type 1.

Sleep
2025

An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions.

Current biology : CB
2025

Narcolepsy Is Associated With Subclinical Cardiovascular Disease as Early as Childhood: A Big Data Analysis.

Journal of the American Heart Association
2025

Altered functional connectivity and spatiotemporal dynamics in individuals with central disorders of hypersomnolence.

Frontiers in neuroscience
2025

Hard road to climb: blunted academic and professional trajectories and effort-reward imbalance for people with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

Clinical and objective correlates of disrupted nighttime sleep in pediatric narcolepsy type 1.

Sleep medicine
2025

Sex effect on time to diagnosis and clinical features of narcolepsy type 1 and 2.

Sleep medicine
2025

Diagnostic value of nocturnal sleep-onset rapid eye movement sleep period for narcolepsy type 1 and 2 in a tertiary sleep centre.

Sleep medicine
2025

Spectral and Microstate EEG Analysis in Narcolepsy Type 1 and Type 2 Across Sleep Stages.

Brain topography
2025

Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial.

CNS drugs
2025

Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial.

CNS drugs
2025

A Survey of People Living with Narcolepsy in the USA: Path to Diagnosis, Quality of Life, and Treatment Landscape from the Patient's Perspective.

CNS drugs
2025

Therapeutic Use of γ-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy.

CNS drugs
2025

Rising pressure to understand the risks of hypertension in children with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

Phenotypic clusters of narcolepsy type 1: Insights from age of onset, weight gain, sleep patterns, and impulsivity.

Sleep medicine
2025

Use of Portable 24-Hour Polysomnography as Alternative Diagnostic Tool for Narcolepsy Type 1 in Adults and Children.

Neurology
2025

[Narcolepsy type 1 and hypocretin neurons].

Ugeskrift for laeger
2025

Determinants of substance use patterns in patients with narcolepsy type 1: A multi-center comparative cross-sectional study.

Sleep medicine
2025

Regional cerebral blood perfusion impairment in type 1 narcolepsy patients: An arterial spin labeling study.

Sleep medicine
2025

Prevalence of narcolepsy in representative samples of the general population of North America, Europe, and South Korea.

Psychiatry research
2025

Quality of life and its associates in narcolepsy 1 and 2 types and idiopathic hypersomnia.

Sleep medicine
2025

Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.

Sleep medicine
2025

MRI-based surrogates of brain clearance in narcolepsy type 1.

Journal of sleep research
2025

Pons metabolite alterations in narcolepsy type 1.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2025

Effort/reward imbalance and comorbidities burden in academic and professional careers of patients with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

An inter-rater variability study between human and automatic scorers in 5-s mini-epochs of sleep.

Sleep medicine
2024

Treatment of Narcolepsy Type 1 With Orexin: A Systematic Review.

Cureus
2025

Roles of cerebrospinal fluid metabolites in mediating the relationship between cathepsins and narcolepsy type 1: A comprehensive Mendelian randomization analysis.

Progress in neuro-psychopharmacology &amp; biological psychiatry
2025

Very late onset narcolepsy type 1: a case report and review of the literature.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

Z hypnotics in the management of narcolepsy: a case series.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

Variability of excessive daytime sleepiness and cataplexy according to seasonality: A study in central disorders of hypersomnolence.

Journal of sleep research
2025

Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection.

Annals of clinical and translational neurology
2024

Impaired Vigilance in Patients with Narcolepsy Type 1: A Psychomotor Vigilance Task Study.

Nature and science of sleep
2024

The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.

International journal of molecular sciences
2025

Social support and isolation in narcolepsy and idiopathic hypersomnia: An international survey.

Sleep medicine
2024

Is CSF hypocretin level useful for differentiating narcolepsy type 1 and 2?

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Physiological and psychological stress reactivity in narcolepsy type 1.

Sleep
2025

Measuring energy expenditure in narcolepsy using doubly labeled water and respiration chamber calorimetry.

Sleep
2024

Associations between T-cell traits and narcolepsy type 1: new insights from a Mendelian randomization study.

Frontiers in neurology
2023

Exploring the Literature on Narcolepsy: Insights into the Sleep Disorder That Strikes during the Day.

NeuroSci
2025

The Lehigh Valley Health Network Narcolepsy Cohort: clinical and polysomnographic analysis of 304 cases.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

Patient experiences of narcolepsy and idiopathic hypersomnia in the Nordics: a patient journey map.

Journal of sleep research
2024

Psychiatric comorbidity in Danish patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia: a case-control study.

Sleep advances : a journal of the Sleep Research Society
2024

Alterations in the DTI-ALPS index and choroid plexus volume are associated with clinical symptoms in participants with narcolepsy type 1.

Sleep medicine
2025

Impaired sleep-dependent memory consolidation in pediatric narcolepsy type 1.

Sleep
2025

Characterizing disrupted nighttime sleep and associated functional outcomes in youth with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2025

International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (iSPHYNCS): the impact of psychiatric comorbidities on daily life in central disorders of hypersomnolence-a vicious circle.

Journal of sleep research
2025

Probabilistic sleep staging in MSLTs across hypersomnia disorders.

Sleep
2024

Predicting Depression Among Chinese Patients with Narcolepsy Type 1: A Machine-Learning Approach.

Nature and science of sleep
2025

Increased neutrophil-to-lymphocyte ratio as a possible marker to detect neuroinflammation in patients with narcolepsy type 1.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2024

Co-occurrence of anxiety and depressive symptoms, suicidal thoughts, and hopelessness in patients with narcolepsy type 1.

Sleep medicine
2024

Altered functional connectivity and spatiotemporal dynamics in individuals with sleep disorders.

bioRxiv : the preprint server for biology
2024

TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models.

Scientific reports
2024

Recent insights into the pathophysiology of narcolepsy type 1.

Sleep medicine reviews
2024

CSF-profile and hypocretin levels in children with narcolepsy type 1 and 2.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2024

Clinical features and mechanisms of neck myoclonus in narcolepsy.

Sleep medicine
2024

Immune Reconstitution Inflammatory Syndrome Due to HIV Treatment as a Potential Trigger: A Case Report with Late-Onset Narcolepsy.

Nature and science of sleep
2024

Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial.

Clinical therapeutics
2024

Insights from a 10-year Australasian idiopathic hypersomnia patient data registry study.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2024

Association between human leukocyte antigen class II-DR-DQ and narcolepsy: a case control study.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2024

Major alteration of motor control during rapid eye movements sleep in mice models of sleep disorders.

Sleep
2024

Serum N-Glycan Profiling of Patients with Narcolepsy Type 1 Using LC-MS/MS.

ACS omega
2024

Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary.

Journal of comparative effectiveness research
2024

Exploring the association between hypocretin-1 levels and bone mineral content in patients with narcolepsy: A cross-sectional study.

Sleep medicine
2024

Association between cytokines and symptoms of depression and anxiety in patients with type 1 narcolepsy.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2024

Validation and performance of the sleep inertia questionnaire in central disorders of hypersomnolence.

Sleep medicine
2024

The nature and magnitude of cognitive impairment in narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia: a meta-analysis.

Sleep advances : a journal of the Sleep Research Society
2024

CSF dynamics of orexin and β-amyloid42 levels in narcolepsy and Alzheimer's disease patients: a controlled study.

Neuroscience letters
2024

Infection, vaccination and narcolepsy type 1: Evidence and potential molecular mechanisms.

Journal of neuroimmunology
2025

Ageing-related modification of sleep and breathing in orexin-knockout narcoleptic mice.

Journal of sleep research
2025

The electroretinography to identify biomarkers of idiopathic hypersomnia and narcolepsy type 1.

Journal of sleep research
2024

Barriers to therapy adherence in narcolepsy.

Sleep medicine
2024

[Constructing a cataplexy face prediction model for narcolepsy type 1 based on ResNet-18].

Zhonghua yi xue za zhi
2024

Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.

Neurology
2025

Narcolepsy and rapid eye movement sleep.

Journal of sleep research
2024

Novel biomarkers derived from the Maintenance of Wakefulness Test as predictors of sleepiness and response to treatment.

Sleep
2024

Impaired cognition in narcolepsy: clinical and neurobiological perspectives.

Sleep
2024

Evaluating routine blood and cerebrospinal fluid samples in narcolepsy patients.

Scandinavian journal of clinical and laboratory investigation
2024

High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2.

International journal of immunogenetics
2024

The value of using ELISA to detect orexin-A in cerebrospinal fluid in the diagnosis of narcolepsy.

Medicine
2024

The Changed Nocturnal Sleep Structure and Higher Anxiety, Depression, and Fatigue in Patients with Narcolepsy Type 1.

Nature and science of sleep
2024

An Unusual Cause of Increasing Excessive Daytime Sleepiness in a CPAP-treated Obstructive Sleep Apnea Patient.

Sleep science (Sao Paulo, Brazil)
2024

Machine learning-Based model for prediction of Narcolepsy Type 1 in Patients with Obstructive Sleep Apnea with Excessive Daytime Sleepiness.

Nature and science of sleep
2024

Development and validation of a machine learning model for prediction of comorbid major depression disorder among narcolepsy type 1.

Sleep medicine
2024

Navigating narcolepsy: exploring coping strategies and their association with quality of life in patients with narcolepsy type 1.

Scientific reports
2024

"Oh My Sleeping Child" … Narcolepsy Type 1 in a 22-Month-Old Boy.

Child neurology open
2024

Executive function performance in children and adolescent patients with narcolepsy type 1.

Sleep medicine
2024

Challenges in the Management of Narcolepsy in a Resource Limited Setting: A Case Report.

Cureus
2024

Cataplexy Mistaken for Seizures in a Patient With Undiagnosed Narcolepsy Type I.

Cureus
2024

Autoimmune encephalitis mediated by postvaccination and infection of SARS-CoV-2 in a patient with a narcolepsy type 1.

Revista de neurologia
2023

Atypical isolated cataplexy: two case reports and a mini-review.

Neurocase
2024

Microglia Density and Its Association With Disease Duration, Severity, and Orexin Levels in Patients With Narcolepsy Type 1.

Neurology
2024

Identifying time-resolved features of nocturnal sleep characteristics of narcolepsy using machine learning.

Journal of sleep research
2024

Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.

Journal of autoimmunity
2024

Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2024

Exploring sleep characteristics in Chinese patients with narcolepsy: insights from the nocturnal sleep onset rapid eye movement period (nSOREMP).

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2024

MRS study on the correlation between frontal GABA+/Glx ratio and abnormal cognitive function in medication-naive patients with narcolepsy.

Sleep medicine
2024

Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial.

Sleep medicine: X
2024

Tetrad of Narcolepsy Type 1: Treatment and Management.

Cureus
2024

The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study: feasibility of long-term monitoring with Fitbit smartwatches in central disorders of hypersomnolence and extraction of digital biomarkers in narcolepsy.

Sleep
2024

Temporal patterns of sleep latency in central hypersomnia and attention deficit hyperactivity disorder: a cluster analysis exploration using Multiple Sleep Latency Test.

Frontiers in psychiatry
2024

Theory of Mind impairment in childhood narcolepsy type 1: a case-control study.

Brain communications
2024

Effectiveness of an intervention program on physical activity in children with narcolepsy type 1.

Sleep medicine
2024

Potential immunological triggers for narcolepsy and idiopathic hypersomnia: Real-world insights on infections and influenza vaccinations.

Sleep medicine
2024

Absence of specific autoantibodies in patients with narcolepsy type 1 as indicated by an unbiased random peptide-displayed phage screening.

PloS one
2024

Cortical thickness and sub-cortical volumes in post-H1N1 narcolepsy type 1: A brain-wide MRI case-control study.

Sleep medicine
2024

Agrypnia Excitata and Supranuclear Vertical Gaze Palsy Linked to Anti-Ma Encephalitis.

Movement disorders clinical practice
2024

Eating disorders in narcolepsy type 1: Evidence from a cross-sectional Italian study.

Journal of sleep research
2024

Microstructural White Matter Abnormalities in Children and Adolescents With Narcolepsy Type 1.

Pediatric neurology
2024

Sex disparities in clinical features and burden of narcolepsy type 1.

Journal of sleep research
2024

Cell-based vs enzyme-linked immunosorbent assay for detection of anti-Tribbles homolog 2 autoantibodies in Chinese patients with narcolepsy.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2024

Association between cytokines and fatigue in patients with type 1 narcolepsy.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2024

Downregulation of hypocretin/orexin after H1N1 Pandemrix vaccination of adolescent mice.

Sleep
2024

Late-onset narcolepsy type 1 comorbid with anti-IgLON5 disease in an older male patient.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
2023

The Perfect Storm: A Case of Rapid-Onset Obesity With Hypoventilation, Hypothalamic, Autonomic Dysregulation, Neuroendocrine Tumor (ROHHADNET) With Heart Failure, Narcolepsy, and a Rare Location of a Pelvic Neuroendocrine Tumor.

Cureus
2024

Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in Narcolepsy type 2.

Sleep
2024

Identification of bidirectional causal links between gut microbiota and narcolepsy type 1 using Mendelian randomization.

Sleep
2023

Case report: Excessive daytime sleepiness as a presenting manifestation of autoimmune glial fibrillary acidic protein astrocytopathy.

Frontiers in immunology
2024

Role of Daytime Continuous Polysomnography in the Diagnosis of Pediatric Narcolepsy Type 1.

Neurology
2023

Prevalence and incidence of narcolepsy symptoms in the US general population.

Sleep medicine: X
2024

Connecting the dots: An updated review of the role of autoimmunity in narcolepsy and emerging immunotherapeutic approaches.

Sleep medicine
2024

Dosing and transition characteristics in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study.

Sleep medicine
2024

Work productivity and activity impairment in patients with narcolepsy type 1.

Journal of sleep research
2023

The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I.

Frontiers in immunology
2024

Investigation of anti-neuronal antibodies and disparity in central hypersomnias.

Sleep medicine
Ver todos os 285 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Narcolepsia tipo 1.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Narcolepsia tipo 1

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Patient-reported experiences of cognitive difficulties and their impact on daily life in narcolepsy type 1.
    Frontiers in neurology· 2026· PMID 41859399mais citado
  2. Increased Numbers of CD4+ T-Cells in the Hypocretin/Orexin Region of Narcolepsy Type 1.
    Annals of neurology· 2026· PMID 41830424mais citado
  3. Bioinformatics identification and experimental validation of hub genes associated with narcolepsy type 1.
    Journal of clinical and translational science· 2026· PMID 41694065mais citado
  4. Unravelling Narcolepsy: A Series of Complex Pediatric Cases.
    Neurology. Clinical practice· 2026· PMID 41669756mais citado
  5. Glymphatic dysfunction and its association with clinical symptom severity in narcolepsy type 1: a case-control DTI-ALPS study.
    BMC neurology· 2026· PMID 41593452mais citado
  6. Functional Regression Methods for Estimating 24-Hour Ambulatory Blood Pressure and Heart Rate Parameters in Narcolepsy Type 1.
    Digit Biomark· 2026· PMID 41994626recente
  7. Aquaporin-4 in Narcolepsy Type 1: Investigation of Perivascular Fluid Movement in Sleep Disorders.
    Ann Clin Transl Neurol· 2026· PMID 41981775recente
  8. Impaired attention in pediatric narcolepsy type 1.
    J Clin Sleep Med· 2026· PMID 41954826recente
  9. Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma.
    BMJ Case Rep· 2026· PMID 41942168recente
  10. Classification of narcolepsy type 1 using machine learning on Stanford Cataplexy Questionnaire responses and HLA-DQB1∗06:02.
    Sleep Med· 2026· PMID 41916140recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:2073(Orphanet)
  2. MONDO:0016158(MONDO)
  3. GARD:7162(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56026918(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Narcolepsia tipo 1
Compêndio · Raras BR

Narcolepsia tipo 1

ORPHA:2073 · MONDO:0016158
Prevalência
1-5 / 10 000
Herança
Unknown
CID-10
G47.4 · Narcolepsia e cataplexia
CID-11
Ensaios
18 ativos
Início
Adolescent, Adult, Childhood
Prevalência
30.0 (Europe)
MedGen
UMLS
C0751362
Repurposing
3 candidatos
ephedrineadrenergic receptor agonist
ephedrine-(racemic)dopamine reuptake inhibitor
solriamfetol
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades